Close Menu

NEW YORK (GenomeWeb) – ArcherDx said today that it has entered a research collaboration agreement with the University College London (UCL) and the Francis Crick Institute on lung cancer research.

As part of the agreement, the partners will apply ArcherDx's anchored multiplex PCR (AMP) technology to detect disease recurrence in lung cancer patients from cell-free circulating tumor DNA as part of the UCL-sponsored Tracking Lung Cancer Evolution Through Treatment (TRACERx) study.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.